Complications, Compliance, and 3-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage

Document Type

Article

Publication Date

2-1-2023

Publication Title

Ophthalmic Surg Lasers Imaging Retina

Keywords

Humans, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Bevacizumab, Diabetes Mellitus, Diabetic Retinopathy, Intravitreal Injections, Vascular Endothelial Growth Factor A, Vitrectomy, Vitreous Hemorrhage

Abstract

BACKGROUND AND OBJECTIVE: To report the 3-year outcomes for endolaserless vitrectomy with intravitreal aflibercept injection (IAI) monotherapy for proliferative diabetic retinopathy (PDR)-related vitreous hemorrhage (VH).

MATERIALS AND METHOD: Eyes underwent endolaserless vitrectomy and received one preoperative and intraoperative IAI followed by randomization to a q8week or q16week IAI group. Additional IAI was administered as needed.

RESULTS: 31/40 eyes were randomized (14 q8week eyes, 17 q16week eyes). Through 152 weeks, q8week and q16week eyes received 18.6 and 12.1 IAI, respectively. Q8week eyes observed a 34 letter visual acuity (VA) increase (P = 0.003) compared to a 27 letter increase in the q16week group (P = 0.013).

CONCLUSIONS: Endolaserless vitrectomy with aflibercept monotherapy for PDR-related VH provides significant long-term visual gains. Frequent IAI is required for fewer proliferative consequences.

Medical Subject Headings

Humans; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetes Mellitus; Diabetic Retinopathy; Intravitreal Injections; Vascular Endothelial Growth Factor A; Vitrectomy; Vitreous Hemorrhage

PubMed ID

36780633

Volume

54

Issue

2

First Page

89

Last Page

96

Find It @ Sladen

Share

COinS